Ontario invests CAD 18 million to expand medical isotope production at McMaster Nuclear Reactor

Mechanism

The Ontario government's CAD 18 million grant funds a capacity expansion at the McMaster Nuclear Reactor (MNR) in Hamilton, one of a small number of Western research reactors producing clinical-grade medical isotopes. The funding covers moving the reactor to continuous 24/7 operation (from its prior part-time production schedule), adding 16 new jobs, and lifting research capacity by a stated 300%. Output is projected to rise from ~70,000 to up to 84,000 custom-isotope treatments annually, covering Holmium-166 (liver cancer) and Iodine-125 (prostate cancer, ocular and brain tumour brachytherapy/imaging).

The grant sits inside a broader provincial isotope-security push: Ontario launched the Nuclear Isotope Innovation Council of Ontario (NIICO) in July 2025 as an advisory panel tasked with doubling the province's medical-isotope output over four years, leveraging Ontario's existing nuclear fleet (OPG, Bruce Power) alongside university reactors like McMaster's. Severity is set at 2: the figure is small in absolute terms (CAD 18m) relative to Ontario's other industrial-policy commitments in the register, but it is a precisely quantified, already-disbursed grant with clear production-capacity metrics, so severity_basis: quant applies.

Downstream implications

• Reduces Western reliance on Russia/South Africa-linked isotope supply

chains for niche radiopharmaceuticals — part of the same allied "reshore strategic medical/nuclear inputs" logic seen in the Darlington SMR equity investment and other Ontario nuclear-fleet commitments already in the register.

• Watch for further NIICO-driven funding announcements as Ontario works

toward its four-year isotope-output-doubling target; those would be responds_to candidates for this filing.

• Establishes McMaster as a scaled-up node in the North American medical

isotope supply chain, relevant to any future critical-healthcare-inputs resilience tracking.

Open questions

• Whether the CAD 18 million is a one-time capital grant or the first

tranche of a multi-year commitment tied to NIICO's doubling target.

• Export destinations for McMaster-produced isotopes (GTA listed the United

States as an affected jurisdiction but gave no further detail).

• Whether other Ontario/federal isotope-production sites (e.g., Bruce Power)

receive parallel funding under the same NIICO push.